108102038 1739452481051 Gettyimages 2198663519 Hims Hers Jpeg V Hims & hers (hims) stock jumped 7% after partnering with eli lilly for glp 1 drugs. j.p. morgan initiated coverage with a $35 target and overweight rating. Indianapolis, april 1, 2025 – eli lilly and company (nyse: lly) has no affiliation with hims & hers. zepbound (tirzepatide) can be prescribed by any licensed healthcare professional.
Hims Hers To Sell Eli Lilly S Zepbound Modern Healthcare Hims & hers says that, in addition to the weight loss medication, it will provide comprehensive support services, 24 7 direct access to a care team, personalized nutrition guidance, ongoing clinical check ins, and peer support to its customers. is lly stock a buy? the stock of eli lilly has a consensus strong buy rating among 19 wall street. Hims & hers (hims) stock rose 7% after expanding its eli lilly deal, adding zepbound prescriptions to its glp 1 platform via lillydirect. Saham hims & hers naik 7% berkat perluasan kemitraan saham hims & hers health (nyse:hims) naik 7% menyusul pengumuman bahwa platformnya kini akan memfasilitasi resep untuk portofolio obat penurun berat badan eli lilly. langkah ini secara signifikan memperluas akses pelanggan terhadap perawatan glp 1 yang populer, efektif, dan disetujui fda. Hims & hers health can now connect its customers with self pay prices for eli lilly's weight loss drugs. hims stock popped.
Eli Lilly Denies Hims Hers Affiliation Over Zepbound Access Modern Saham hims & hers naik 7% berkat perluasan kemitraan saham hims & hers health (nyse:hims) naik 7% menyusul pengumuman bahwa platformnya kini akan memfasilitasi resep untuk portofolio obat penurun berat badan eli lilly. langkah ini secara signifikan memperluas akses pelanggan terhadap perawatan glp 1 yang populer, efektif, dan disetujui fda. Hims & hers health can now connect its customers with self pay prices for eli lilly's weight loss drugs. hims stock popped. Earlier this week, hims & hers health said clinicians on its platform can now prescribe eli lilly glp 1 weight loss drugs, which will be filled through lillydirect, adding to existing access to novo nordisk’s wegovy and other branded treatments. this move strengthens hims & hers’ role as a prescribing hub in the fast growing glp 1 care ecosystem by plugging directly into major drugmakers. Hims & hers stock rallied 7% after partnering with eli lilly for glp 1 access. j.p. morgan initiated at overweight with a $35 target on growth potential. Hims & hers health just made its most significant move yet in the race to own the weight loss market, and investors responded immediately. shares of the telehealth company surged 7 percent after it announced an expanded platform allowing licensed providers to prescribe eli lilly’s weight loss medications directly to customers. the deal gives hims & hers users access to zepbound vials and. Key highlights shares of hims & hers surged 7% following news of a broadened collaboration with eli lilly healthcare providers using the platform can now order zepbound vials, kwikpen, and foundayo through lillydirect fulfillment this announcement arrives roughly one month after a comparable agreement with novo nordisk for wegovy distribution leerink partners analyst michael cherny raised.
Comments are closed.